Author Topic: Alemtuzumab under scrutiny because of risk of stroke in some patients with MS  (Read 187 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest

The Lancet (April 27, 2019) contains an article on this topic though there is no easy access to it. However, another article (from Lancet Neurology, February 15) (see link below) explains the situation under discussion:


Quote
Reports of stroke in patients having taken alemtuzumab for multiple sclerosis prompt a safety review by the European Medicines Agency.


The February 15 article, "Intracerebral hemorrhage during alemtuzumab administration":

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30076-6/fulltext
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest


Presented at the annual AAN conference, "Spontaneous Intracerebral Hemorrhage During Administration of Alemtuzumab for Multiple Sclerosis: A Case Series":


http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-001167.pdf




MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
149 Views
Last post September 16, 2016, 11:36:28 am
by agate
0 Replies
100 Views
Last post August 02, 2019, 02:55:41 pm
by agate
0 Replies
87 Views
Last post November 03, 2019, 07:27:43 pm
by agate
0 Replies
16 Views
Last post January 20, 2023, 09:14:40 pm
by agate
0 Replies
13 Views
Last post September 27, 2023, 10:04:11 pm
by agate